Gilead Sciences Sees Increased Institutional Investment

HF Advisory Group boosts stake in biopharmaceutical company by 66.5% in Q4 2025

Apr. 2, 2026 at 11:13am

Got story updates? Submit your updates here. ›

HF Advisory Group LLC, an investment management firm, increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 66.5% during the fourth quarter of 2025, according to a recent SEC filing. The fund now owns 33,076 shares of the biopharmaceutical company's stock, valued at $4.06 million.

Why it matters

Gilead Sciences is a major player in the pharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. The increase in institutional investment, particularly from a firm like HF Advisory Group, signals confidence in the company's long-term prospects and growth potential.

The details

According to the filing, HF Advisory Group added 13,212 shares of Gilead Sciences to its portfolio during the fourth quarter. This brings the firm's total holdings in the company to 33,076 shares. The increased investment suggests HF Advisory Group sees value in Gilead's product pipeline and believes the stock is undervalued.

  • The SEC filing was made on April 2, 2026, covering the fourth quarter of 2025.

The players

HF Advisory Group LLC

An investment management firm that has increased its stake in Gilead Sciences by 66.5% in the fourth quarter of 2025.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The increased institutional investment in Gilead Sciences suggests that the company's fundamentals and growth prospects remain strong, even as it navigates a competitive pharmaceutical landscape. This could signal potential upside for the stock as investors recognize the value in Gilead's diverse product portfolio and pipeline.